In 1901, a 51-year-old woman named Auguste Deter was admitted to the Frankfurt Psychiatric Hospital in Germany. She was experiencing memory loss, disorientation, and behavioural changes that no one could explain. Her doctor, a German psychiatrist and neuropathologist named Alois Alzheimer, was determined to understand why.
When Auguste passed away in 1906, Dr. Alzheimer examined her brain under a microscope and found something interesting: abnormal protein deposits between nerve cells – what we now call amyloid plaques – and twisted fibres inside neurons, known as neurofibrillary tangles. He presented his findings that same year at a psychiatric conference in Tübingen, and the medical world would never be the same.
The disease was later named after him by his colleague Emil Kraepelin, and Alois Alzheimer’s name became permanently woven into the history of medicine. If you ever find yourself in Bavaria, Germany, you can even visit the Alzheimer Haus in Marktbreit – the birthplace of Alois Alzheimer, now preserved as a museum and exhibit space dedicated to his life and legacy.
For much of the 20th century, Alzheimer’s disease was poorly understood and widely underdiagnosed – often dismissed as “just old age.” That began to change in the 1970s and 80s, when researchers started mapping the biological mechanisms behind the disease and recognizing its true scale. By the 1990s, the first medications were approved: cholinesterase inhibitors like donepezil, which help maintain levels of acetylcholine – a neurotransmitter critical for memory and communication between brain cells. A few years later, memantine was added to the toolkit, offering further symptom management by regulating glutamate activity. These weren’t cures, but they were a turning point: proof that the disease could be addressed medically, and that people living with Alzheimer’s could be supported in meaningful ways.
Beyond the science, something equally important has been shifting – what it means to live with Alzheimer’s today. Support ecosystems have evolved significantly – though the picture looks different depending on where in the world you are. In higher-income countries, dedicated memory care programs, caregiver training initiatives, and community-based services now exist at a scale that simply wasn’t available to previous generations. But across lower- and middle-income countries, where formal healthcare infrastructure may be limited, a different kind of backbone has emerged: NGOs, patient associations, and community advocacy groups that step in where governments cannot. They train local caregivers, often family members with no medical background, to recognize symptoms and respond with confidence. They run awareness campaigns in communities where dementia is still widely misunderstood or attributed to spiritual causes. They create safe spaces – sometimes nothing more than a weekly gathering – where families can share the weight of a diagnosis they may be carrying entirely alone. They advocate for policy change, push for Alzheimer’s to be recognized in national health agendas, and connect isolated families to whatever local resources exist. These organizations are doing extraordinary work – and they are an essential part of the global Alzheimer’s story.
On the treatment front, the arrival of amyloid-targeting therapies marks a genuine milestone – but the work is far from over. Translating scientific breakthroughs into treatments that reach patients everywhere, regardless of where they live or what resources they have access to, remains one of the great challenges of the years ahead. Early diagnosis, which these therapies depend on to be effective, is itself a hurdle that much of the world has yet to clear. Here too, however, progress is visible. Digital tools, AI-assisted diagnostics, and remote monitoring technologies are beginning to extend the reach of specialist care beyond major hospitals and into communities that have historically been left behind – offering a glimpse of a future where geography is no longer a barrier to early detection.
Alzheimer’s disease has come a long way from a single case study in Frankfurt. What began as an observation under a microscope has grown into a global scientific and human mission – one shaped as much by the communities rallying around those affected as by the breakthroughs emerging from research labs. That progress belongs to many hands: researchers, yes, but also the clinicians, caregivers, patient advocates, and community organizations around the world who have refused to let the disease remain invisible.